Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of PLD1 as molecular marker for evaluating sensitivity of tumor patients to chemotherapeutic drugs

A technology for tumor patients and uses, applied in biological testing, analytical materials, instruments, etc., to achieve objective, timely and accurate effects of drug resistance

Pending Publication Date: 2022-07-22
TIANJIN TUMOR HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] So far, there is no report on the correlation between the expression level of phospholipase D1 in patients with pancreatic cancer and its sensitivity to chemotherapeutic drugs, curative effect or prognosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PLD1 as molecular marker for evaluating sensitivity of tumor patients to chemotherapeutic drugs
  • Application of PLD1 as molecular marker for evaluating sensitivity of tumor patients to chemotherapeutic drugs
  • Application of PLD1 as molecular marker for evaluating sensitivity of tumor patients to chemotherapeutic drugs

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0036] Experimental Example 1 Correlation analysis between PLD1 expression in pancreatic cancer tissue and the corresponding clinical efficacy prediction or prognosis in pancreatic cancer patients

[0037] 1 Sample collection

[0038] In this experiment, 80 patients with pancreatic cancer initially diagnosed and surgically resected in Tianjin Cancer Hospital from 2012 to 2015 were collected. The patients did not receive any relevant targeted chemotherapy before surgery (patients did not receive chemotherapy before surgery, and received gemcitabine therapy after surgery. Comparison of The relationship between the level of PLD1 expression in preoperative tissue and the sensitivity of postoperative gemcitabine response), and the pathology department of the hospital was invited to complete the section work. In addition, age, gender, degree of differentiation, TNM stage, anatomical position of tumor relative to pancreas, and capsular invasion were counted according to medical recor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of PLD1 as a molecular marker for evaluating sensitivity of tumor patients to chemotherapeutic drugs. The invention finds that the expression level of PLD1 in pancreatic ductal adenocarcinoma is related to the sensitivity to gemcitabine, the expression of PLD1 in pancreatic cancer tumor cell nucleuses is related to the differentiation degree and T staging of tumors, and the total lifetime of patients with high expression of PLD1 in cancer ductal cell nucleuses is short, which indicates that the patients with high expression of PLD1 in pancreatic cancer ductal cells are related to postoperative recurrence and metastasis, and the patients with high expression of PLD1 in pancreatic cancer ductal cells are related to postoperative recurrence and metastasis. The biomarker is used for estimating prognosis of pancreatic cancer patients, recurrence and metastasis of tumors and tumor differentiation degree. Therefore, the invention can guide clinical treatment of pancreatic ductal adenocarcinoma and reverse gemcitabine drug resistance. The PLD1 biomarker related to patient prognosis is found in a tissue specimen of a pancreatic cancer patient, so that the drug resistance degree of the patient to pre-gemcitabine can be evaluated more directly, objectively, timely and accurately, and the method is economical, rapid and more beneficial to actual operation.

Description

technical field [0001] The present invention relates to a molecular marker for estimating the sensitivity of tumor to chemotherapeutic drug treatment, in particular to a molecular marker for estimating the sensitivity of pancreatic cancer to gemcitabine treatment, and the present invention further relates to a detection reagent for predicting the curative effect or prognosis of pancreatic cancer The box belongs to the field of molecular markers for the sensitivity of pancreatic cancer to chemotherapeutic drug treatment. Background technique [0002] Pancreatic cancer, a highly malignant tumor of the digestive tract, ranks fourth in the world in terms of cancer death, after colorectal cancer, with a five-year survival rate of only 10%. In recent years, it has also been due to people smoking and drinking. The incidence of irregular life and diet is increasing year by year, and the mortality rate is as high as 8%. Due to the insidious onset of pancreatic cancer in the early s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68G01N33/577
CPCG01N33/6893G01N33/577G01N2800/7028G01N2800/06
Inventor 郝继辉王宏伟富丹琪
Owner TIANJIN TUMOR HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com